Neil Josephson - 14 Oct 2026 Form 4 Insider Report for Iambic Therapeutics, Inc. (IAM)

Reporting relationship: Chief Medical Officer
Issuer ticker: IAM
Reported as of: 14 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Oct 2026, 16:12:01 UTC
Prior SEC filing: 14 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Sunny Chang, by power of attorney

Key filing fact

Neil Josephson filed Form 4 for Iambic Therapeutics, Inc. (IAM) on 16 Oct 2026.

Key facts

This page summarizes Neil Josephson's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Oct 2026, 16:12.

Change

Previous filing in this sequence was filed on 14 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001864141 Primary reporting owner

Josephson Neil

Relationship: Chief Medical Officer
Address: C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO
Signature: /s/ Sunny Chang, by power of attorney
Signature date: 16 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IAM transaction

Common Stock

Award

Transaction value
Shares: +31,000
Change %: +77%
Price: $0.000000^*
Shares after: 71,459
Date: 14 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IAM transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +185,900
Change %
Price: $0.000000^*
Shares after: 185,900
Date: 14 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 185,900
Exercise price: $16.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported shares are represented by restricted stock units, or RSUs, which vest as follows: 25% of the RSUs vest on September 10, 2027 and the remaining RSUs vest in twelve equal quarterly installments beginning on December 10, 2027.

Footnote F2

Twenty-five percent of the shares subject to the option vest on October 14, 2027 and 1/48th of the shares vest monthly thereafter.